NewGenIvf Group (NASDAQ:NIVF – Get Free Report) and Progyny (NASDAQ:PGNY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
Valuation and Earnings
This table compares NewGenIvf Group and Progyny”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
NewGenIvf Group | $5.14 million | 0.54 | $130,000.00 | N/A | N/A |
Progyny | $1.09 billion | 1.24 | $62.04 million | $0.63 | 23.81 |
Progyny has higher revenue and earnings than NewGenIvf Group.
Profitability
Net Margins | Return on Equity | Return on Assets | |
NewGenIvf Group | N/A | N/A | N/A |
Progyny | 5.54% | 11.97% | 8.43% |
Insider & Institutional Ownership
66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Comparatively, 12.3% of Progyny shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings for NewGenIvf Group and Progyny, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NewGenIvf Group | 0 | 0 | 0 | 0 | N/A |
Progyny | 0 | 7 | 5 | 0 | 2.42 |
Progyny has a consensus price target of $27.73, suggesting a potential upside of 84.85%. Given Progyny’s higher probable upside, analysts clearly believe Progyny is more favorable than NewGenIvf Group.
Volatility and Risk
NewGenIvf Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
Summary
Progyny beats NewGenIvf Group on 10 of the 11 factors compared between the two stocks.
About NewGenIvf Group
A SPAC I Acquisition Corp. is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. A SPAC I Acquisition Corp. is based in Singapore.
About Progyny
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.